{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:10:20Z","timestamp":1791868220714,"version":"4.3.4"},"reference-count":49,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011421","name":"Sanofi China Investment Company","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2021,7,17]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>This analysis aims to investigate the efficacy and safety of once-daily lixisenatide add-on treatment to basal insulin in Asian individuals with type 2 diabetes, by baseline body mass index (BMI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Research design and methods<\/jats:title>\n                  <jats:p>Data from all Asian participants in the placebo-controlled GetGoal-Duo 1, GetGoal-L, and GetGoal-L-C Studies were pooled and categorized according to the following BMI subgroups:&lt;25\u2009kg\/m<jats:sup>2<\/jats:sup>, 25\u2013&lt;30\u2009kg\/m<jats:sup>2<\/jats:sup> and \u226530\u2009kg\/m<jats:sup>2<\/jats:sup>. Efficacy and safety of lixisenatide versus placebo were evaluated among BMI subgroups. Multivariable regression analyses were also conducted to explore the potential influence of BMI on efficacy outcomes after adjusting for baseline characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>555 participants were included (mean age 53.9 years, 52.4% men). No significant differences in treatment effect between the BMI subgroups were observed for the changes from baseline to 24 weeks in glycated hemoglobin (HbA1c), fasting plasma glucose, postprandial glucose (PPG), PPG excursion, body weight, BMI, and basal insulin dose with lixisenatide, as well as the change in basal insulin dose at study endpoint and the proportion of participants achieving an HbA1c &lt;7% at 24 weeks (all p values for interaction &gt;0.15). In the multivariable regression analysis, participants in the lowest BMI group had a smaller reduction in body weight over the 24-week treatment period relative to the highest BMI group (p<jats:italic>=<\/jats:italic>0.023).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This post hoc analysis indicates that lixisenatide improved glycemic control regardless of baseline BMI and was well tolerated in Asian individuals unable to achieve their HbA1c target on basal insulin\u00b1oral antidiabetic drugs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjdrc-2021-002290","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T12:23:34Z","timestamp":1630067014000},"page":"e002290","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00975286","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00715624","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01632163","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Wenhuan","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Affair, Sanofi, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minlu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Affair, Sanofi, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Affair, Sanofi, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiu","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Medical Affair, Sanofi, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-1261","authenticated-orcid":false,"given":"Dalong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"2025073112312056000_9.1.e002290.1","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0066"},{"key":"2025073112312056000_9.1.e002290.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62154-6"},{"key":"2025073112312056000_9.1.e002290.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00618-8"},{"key":"2025073112312056000_9.1.e002290.4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41366-020-00698-x","article-title":"Trends in the prevalence of overweight, obesity, and abdominal obesity among Chinese adults between 1993 and 2015","volume":"45","author":"Ma","year":"2021","journal-title":"Int J Obes"},{"key":"2025073112312056000_9.1.e002290.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01336.x"},{"key":"2025073112312056000_9.1.e002290.6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019930"},{"key":"2025073112312056000_9.1.e002290.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30054-X"},{"key":"2025073112312056000_9.1.e002290.8","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S2213-8587(19)30152-4","article-title":"The dietary transition and its association with cardiometabolic mortality among Chinese adults, 1982-2012: a cross-sectional population-based study","volume":"7","author":"He","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025073112312056000_9.1.e002290.9","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12384"},{"key":"2025073112312056000_9.1.e002290.10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3803\/EnM.2015.30.3.263","article-title":"Diabetes in Asians","volume":"30","author":"Rhee","year":"2015","journal-title":"Endocrinol Metab"},{"key":"2025073112312056000_9.1.e002290.11","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1235"},{"key":"2025073112312056000_9.1.e002290.12","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2.354"},{"key":"2025073112312056000_9.1.e002290.13","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0598"},{"key":"2025073112312056000_9.1.e002290.14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(19)30425-5","article-title":"Association of insulin resistance and \u03b2-cell dysfunction with incident diabetes among adults in China: a nationwide, population-based, prospective cohort study","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025073112312056000_9.1.e002290.15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1467-789X.2007.00439.x","article-title":"Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension","volume":"9 Suppl 1","author":"Huxley","year":"2008","journal-title":"Obes Rev"},{"key":"2025073112312056000_9.1.e002290.16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.726"},{"key":"2025073112312056000_9.1.e002290.17","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v3.i6.110"},{"key":"2025073112312056000_9.1.e002290.18","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12098"},{"key":"2025073112312056000_9.1.e002290.19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41366-021-00774-w","article-title":"The unparalleled rise of obesity in China: a call to action","volume":"45","author":"Hemmingsson","year":"2021","journal-title":"Int J Obes"},{"key":"2025073112312056000_9.1.e002290.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2009.10.006"},{"key":"2025073112312056000_9.1.e002290.21","first-page":"390","article-title":"Slow titration and delayed intensification of basal insulin among patients with type 2 diabetes","volume":"24","author":"Mocarski","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"2025073112312056000_9.1.e002290.22","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.722989"},{"key":"2025073112312056000_9.1.e002290.23","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S009"},{"key":"2025073112312056000_9.1.e002290.24","doi-asserted-by":"publisher","DOI":"10.7556\/jaoa.2014.004"},{"key":"2025073112312056000_9.1.e002290.25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials","volume":"20 Suppl 1","author":"Aroda","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025073112312056000_9.1.e002290.26","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0057-y"},{"key":"2025073112312056000_9.1.e002290.27","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.4158\/EP171769.OR","article-title":"Comparing clinical outcomes and costs for different treatment intensification approaches in patients with type 2 diabetes uncontrolled on basal insulin: adding glucagon-like peptide 1 receptor agonists versus adding rapid-acting insulin or increasing basal insulin dose","volume":"23","author":"Levin","year":"2017","journal-title":"Endocr Pract"},{"key":"2025073112312056000_9.1.e002290.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-22443-1","article-title":"Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis","volume":"8","author":"Yoon","year":"2018","journal-title":"Sci Rep"},{"key":"2025073112312056000_9.1.e002290.29","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2454"},{"key":"2025073112312056000_9.1.e002290.30","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2462"},{"key":"2025073112312056000_9.1.e002290.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01618.x"},{"key":"2025073112312056000_9.1.e002290.32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/dom.13072","article-title":"Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: the GetGoal-L-C randomized trial","volume":"20","author":"Yang","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025073112312056000_9.1.e002290.33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13098-015-0104-6","article-title":"Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials","volume":"7","author":"Eto","year":"2015","journal-title":"Diabetol Metab Syndr"},{"key":"2025073112312056000_9.1.e002290.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15268-3"},{"key":"2025073112312056000_9.1.e002290.35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/dom.12815","article-title":"Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials","volume":"19","author":"Blonde","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2025073112312056000_9.1.e002290.36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2042018817752315","article-title":"A review of the new GLP-1 receptor agonist\/basal insulin fixed-ratio combination products","volume":"9","author":"Nuffer","year":"2018","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2025073112312056000_9.1.e002290.37","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0632"},{"key":"2025073112312056000_9.1.e002290.38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1573399812666151223093841","article-title":"Glucagon-Like peptide-1 receptor agonists for type 2 diabetes: a clinical update of safety and efficacy","volume":"12","author":"Drab","year":"2016","journal-title":"Curr Diabetes Rev"},{"key":"2025073112312056000_9.1.e002290.39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41387-018-0068-3","article-title":"Allometric scaling of weight to height and resulting body mass index thresholds in two Asian populations","volume":"9","author":"Hood","year":"2019","journal-title":"Nutr Diabetes"},{"key":"2025073112312056000_9.1.e002290.40","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/dom.12980","article-title":"Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine\/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents","volume":"19","author":"Davies","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2025073112312056000_9.1.e002290.41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13098-016-0151-7","article-title":"Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis","volume":"8","author":"Seino","year":"2016","journal-title":"Diabetol Metab Syndr"},{"key":"2025073112312056000_9.1.e002290.42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/dom.14139","article-title":"Benefits of the fixed-ratio combination of insulin glargine 100\u2009units\/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials","volume":"22 Suppl 4","author":"Terauchi","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2025073112312056000_9.1.e002290.43","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-013-0489-3"},{"key":"2025073112312056000_9.1.e002290.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.11.015"},{"key":"2025073112312056000_9.1.e002290.45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/162718","article-title":"Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus","volume":"2015","author":"Khan","year":"2015","journal-title":"J Diabetes Res"},{"key":"2025073112312056000_9.1.e002290.46","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/jdi.12184","article-title":"Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes","volume":"5","author":"Song","year":"2014","journal-title":"J Diabetes Investig"},{"key":"2025073112312056000_9.1.e002290.47","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1331\/JAPhA.2012.10217","article-title":"Determining predictors of response to exenatide in type 2 diabetes","volume":"52","author":"Anderson","year":"2012","journal-title":"J Am Pharm Assoc"},{"key":"2025073112312056000_9.1.e002290.48","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13055","article-title":"Real-World clinical outcomes and predictors of glycaemic and weight response to exenatide once Weekly in patients with type 2 diabetes: the CIBELES project","volume":"72","author":"Gorgojo-Mart\u00ednez","year":"2018","journal-title":"Int J Clin Pract"},{"key":"2025073112312056000_9.1.e002290.49","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-014-0171-2","article-title":"Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once Weekly: a pooled analysis of patients with type 2 diabetes","volume":"14","author":"Blonde","year":"2015","journal-title":"Cardiovasc Diabetol"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2021-002290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T19:31:29Z","timestamp":1753990289000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2021-002290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,27]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1136\/bmjdrc-2021-002290"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2021-002290","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}